Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Multiple Myeloma, Version 3.2022 Featured Updates to the NCCN Guidelines JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Callander, N. S., Baljevic, M., Adekola, K., Anderson, L. D., Campagnaro, E., Castillo, J. J., Costello, C., Devarakonda, S., Elsedawy, N., Faiman, M., Garfall, A., Godby, K., Hillengass, J., Holmberg, L., Htut, M., Huff, C., Hultcrantz, M., Kang, Y., Larson, S., Liedtke, M., Martin, T., Omel, J., Sborov, D., Shain, K., Stockerl-Goldstein, K., Weber, D., Berardi, R. A., Kumar, R., Kumar, S. K. 2022; 20 (1): 9-19

Abstract

The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, initial workup, treatment, follow-up, and supportive care for patients with various plasma cell neoplasms, including multiple myeloma. These NCCN Guidelines Insights highlight some of the important updates/changes specific to the treatment of patients with multiple myeloma in the 2022 version of the guidelines.

View details for DOI 10.6004/jnccn.2022.0002

View details for Web of Science ID 000807390300006

View details for PubMedID 34991075